000 01512 a2200517 4500
005 20250517170914.0
264 0 _c20180604
008 201806s 0 0 eng d
022 _a1476-5551
024 7 _a10.1038/leu.2017.266
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aNazha, A
245 0 0 _aAdding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.
_h[electronic resource]
260 _bLeukemia
_c12 2017
300 _a2848-2850 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aLeukocytes, Mononuclear
_xdrug effects
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aMutation
650 0 4 _aMyelodysplastic Syndromes
_xdrug therapy
650 0 4 _aPrognosis
650 0 4 _aYoung Adult
700 1 _aAl-Issa, K
700 1 _aHamilton, B K
700 1 _aRadivoyevitch, T
700 1 _aGerds, A T
700 1 _aMukherjee, S
700 1 _aAdema, V
700 1 _aZarzour, A
700 1 _aAbuhadra, N
700 1 _aPatel, B J
700 1 _aHirsch, C M
700 1 _aAdvani, A
700 1 _aPrzychodzen, B
700 1 _aCarraway, H E
700 1 _aMaciejewski, J P
700 1 _aSekeres, M A
773 0 _tLeukemia
_gvol. 31
_gno. 12
_gp. 2848-2850
856 4 0 _uhttps://doi.org/10.1038/leu.2017.266
_zAvailable from publisher's website
999 _c27476484
_d27476484